Ivermectin Prices: Chart, Market Analysis, Price Trends and Forecast 2026

Author : ChemAnalyst Data | Published On : 14 Oct 2026

According to ChemAnalyst, The global Ivermectin Prices experienced an upward trend during the second quarter of 2026, supported by rising production costs, higher chemical feedstock expenses, and regional differences in pharmaceutical demand. The Ivermectin Price Index increased across North America, Asia-Pacific (APAC), and Europe, although the intensity of price movements varied according to local manufacturing conditions, energy expenses, inventory strategies, and purchasing activity. While producers faced growing cost pressures, buyers in several markets remained cautious about procurement volumes amid economic uncertainty and uneven demand recovery.

In North America, Ivermectin Prices rose as higher producer prices and manufacturing expenses influenced pharmaceutical supply chains. Demand for medical products remained supportive, backed by relatively stable employment conditions and increased healthcare expenditure. However, slower industrial activity and changes in energy prices created a mixed cost environment for manufacturers.

In APAC, China recorded an increase in the Ivermectin Price Index, primarily due to higher chemical input costs and rising feedstock expenses. China's extensive chemical manufacturing infrastructure and export capacity supported production availability, but subdued domestic retail demand limited the strength of price increases. The average free-on-board (FOB) price of Ivermectin in China reached approximately USD 98,000/MT during Q2 2026.

In Europe, Germany experienced upward pressure on Ivermectin Prices because of rising industrial producer prices and elevated energy costs. Nevertheless, declining consumer confidence and weak regional demand restricted buyers' willingness to build inventories beyond immediate requirements. These conditions contributed to a market characterized by higher production costs but cautious purchasing behavior.

Overall, Ivermectin Prices in Q2 2026 reflected the interaction between input-cost inflation, pharmaceutical demand, manufacturing capacity, and regional trade conditions. Market participants continued to monitor chemical feedstock availability, electricity prices, inventory levels, and procurement trends to assess the direction of prices in the coming quarters.

Ivermectin Prices in North America

The North American Ivermectin Price Index increased quarter-over-quarter in Q2 2026, with the United States experiencing higher prices amid rising production expenses and steady demand for pharmaceutical products. Manufacturing costs remained a major influence on supplier pricing strategies, as producers faced inflationary pressure across industrial inputs, labor, utilities, and related operating expenses.

The US Producer Price Index (PPI) increased by 5.5% year-over-year in June 2026, highlighting the broader inflationary environment affecting production-oriented industries. Although this figure represents economy-wide producer-price conditions rather than Ivermectin-specific manufacturing costs, it indicates the cost pressures that pharmaceutical manufacturers and their suppliers may have encountered during the quarter. Higher prices for chemical intermediates, solvents, packaging materials, and other manufacturing inputs contributed to concerns about preserving operating margins.

Demand conditions provided additional support to Ivermectin Prices. US retail sales increased by 6.9% year-over-year in May 2026, indicating resilience in consumer spending. While retail sales do not directly measure pharmaceutical demand, the broader spending environment helped support commercial activity across consumer-facing sectors. Healthcare expenditure and continued demand for medical products also contributed to the relatively firm purchasing environment.

Consumer price inflation remained elevated, with the US Consumer Price Index (CPI) rising by 3.5% year-over-year in June 2026. This environment increased cost sensitivity among consumers, distributors, and healthcare purchasers. However, the unemployment rate remained at 4.2%, supporting household income conditions and helping maintain demand across several segments of the economy. Consumer confidence was reported at 91.2 in June 2026, suggesting that purchasing decisions remained influenced by both economic resilience and uncertainty.

Industrial production increased by 0.7% year-over-year in June 2026, indicating comparatively modest growth in the broader industrial sector. For pharmaceutical manufacturers, this environment created a balance between continued production activity and pressure to control operating costs. Manufacturers focused on procurement efficiency, production scheduling, and supplier diversification to manage input-price volatility.

Get Real Time Online for Ivermectin Prices: https://www.chemanalyst.com/Pricing-data/ivermectin-1381

Energy markets also influenced the North American Ivermectin Price Trend. Lower Henry Hub natural gas prices in April 2026 provided some relief to energy-related expenses, although higher retail electricity revenues per kilowatt-hour increased costs for electricity-intensive manufacturing operations. Since pharmaceutical production involves several energy-dependent processes, the combined effect of these movements varied by facility, contract structure, and production technology.

Trade measures introduced by the United States during Q2 2026 further influenced pharmaceutical supply-chain decisions. Importers and manufacturers evaluated alternative sourcing arrangements to reduce exposure to trade-related uncertainty, delivery disruptions, and changes in landed costs. Such diversification strategies can improve supply resilience but may also increase qualification, logistics, and procurement expenses in the short term.

By the end of June 2026, the North American Ivermectin market reflected firm production costs and relatively supportive demand fundamentals. Nevertheless, the extent of further price increases remained dependent on the movement of pharmaceutical-grade raw materials, energy costs, supplier availability, and purchasing volumes.

Why Did Ivermectin Prices Change in June 2026 in North America?

The increase in Ivermectin Prices in North America during June 2026 was primarily associated with higher production costs and continued demand for pharmaceutical products.

Higher producer prices: The 5.5% year-over-year increase in US PPI in June 2026 indicated persistent cost inflation across the broader production economy.
Supportive spending conditions: Retail sales growth of 6.9% in May 2026 and a 4.2% unemployment rate supported overall economic activity and purchasing capacity.
Healthcare demand: Continued expenditure on medical goods and healthcare products helped maintain demand across pharmaceutical supply chains.
Mixed energy costs: Lower natural gas prices offered partial relief, while rising electricity expenses increased manufacturing overheads.
Supply-chain diversification: Changes in US trade conditions encouraged buyers and suppliers to reassess sourcing strategies, potentially increasing short-term procurement costs.

Together, these factors supported the upward movement of the North American Ivermectin Price Index, although individual supplier prices continued to depend on contract terms, order sizes, and product specifications.

Ivermectin Prices in APAC

The APAC Ivermectin Price Index increased quarter-over-quarter in Q2 2026, with China remaining an important manufacturing and export hub. The average FOB price of Ivermectin in China was approximately USD 98,000/MT during the quarter. Rising feedstock prices, higher chemical raw material costs, and inflationary pressure across industrial production contributed to the upward movement in prices.

China's Producer Price Index increased by 4.1% year-over-year in June 2026, indicating rising prices across the industrial supply chain. Although this measure does not isolate pharmaceutical ingredients, it highlights the broader cost environment affecting chemical manufacturers. Ivermectin producers faced potential increases in the cost of intermediates, processing chemicals, utilities, and other production inputs, encouraging suppliers to reassess quotations and protect margins.

Feedstock availability and chemical input prices remained central to the Ivermectin Price Trend in China. Pharmaceutical ingredient manufacturing depends on reliable supplies of chemical intermediates and process materials that meet specified quality requirements. When these inputs become more expensive, manufacturers may experience higher production costs even when overall industrial capacity remains sufficient.

China's industrial environment provided some support for production continuity. Industrial production grew by 5.3% year-over-year in June 2026, indicating continued expansion across the broader industrial sector. Manufacturing activity and established chemical production networks supported access to industrial inputs, while export-oriented suppliers continued to benefit from China's manufacturing scale and established international trade connections.

Chemical exports recorded counter-cyclical growth during Q2 2026, supported by available production capacity and competitive manufacturing costs. This export resilience helped suppliers maintain their presence in international markets despite uneven global demand. However, the effect on Ivermectin Prices depended on product-specific supply availability, order volumes, and the cost of pharmaceutical-grade manufacturing.

Domestic demand remained a limiting factor. Chinese retail sales grew by only 1.0% year-over-year in June 2026, indicating relatively subdued consumer spending. Although retail sales are not a direct indicator of Ivermectin consumption, weak domestic demand can influence distributors' purchasing strategies and encourage more conservative inventory management. Buyers may postpone orders or negotiate more aggressively when downstream sales remain uncertain.

This contrast between rising manufacturing costs and restrained demand shaped the Chinese Ivermectin market during the quarter. Producers faced pressure to maintain selling prices in line with higher input expenses, while customers sought to avoid excessive inventory commitments. As a result, price negotiations increasingly depended on delivery schedules, order size, supplier reliability, and the availability of alternative sources.

China's export position also influenced international procurement decisions. Buyers in other APAC markets and overseas destinations continued to evaluate Chinese suppliers based on cost competitiveness, quality documentation, delivery reliability, and compliance requirements. While a large manufacturing base can help support availability, changes in freight rates, trade policies, and raw material costs may affect the final landed price for importers.

Overall, APAC Ivermectin Prices followed an upward trajectory in Q2 2026, led by rising production expenses in China. The market nevertheless remained sensitive to weak domestic purchasing activity, meaning that higher input costs did not necessarily translate into equally strong demand-driven price increases.

Why Did Ivermectin Prices Change in June 2026 in APAC?

Ivermectin Prices in APAC increased during June 2026 as rising industrial input costs outweighed the restraining effect of subdued domestic demand.

Higher industrial producer prices: China's PPI increased by 4.1% year-over-year in June 2026, indicating broader cost inflation affecting chemical supply chains.
Rising feedstock expenses: Higher chemical raw material prices increased manufacturing costs and encouraged suppliers to revise quotations.
Moderate domestic demand: Retail sales growth of 1.0% in June 2026 limited the strength of demand-side price support.
Expanding industrial production: Industrial output growth of 5.3% supported manufacturing activity and the availability of chemical inputs.
Export competitiveness: Established production capacity and export networks helped Chinese manufacturers sustain international market participation.

The average FOB China price of USD 98,000/MT provided an important reference point for the quarter. Actual transaction prices could vary according to purity specifications, packaging, order volumes, delivery terms, and contractual arrangements.

Ivermectin Prices in Europe

The European Ivermectin Price Index increased quarter-over-quarter in Q2 2026, with Germany experiencing upward pressure from higher industrial input prices and elevated energy expenses. Despite these cost increases, weak domestic and regional demand limited the extent to which manufacturers could pass all additional expenses on to customers.

Germany's producer prices for industrial products increased by 2.2% in May 2026, reflecting a broader cost environment that affected manufacturing industries. For pharmaceutical ingredient suppliers, higher prices for chemical intermediates, solvents, utilities, packaging, and industrial services may contribute to higher production expenses. These pressures were particularly important for manufacturers seeking to preserve profitability while operating in a market characterized by cautious purchasing.

Energy expenses remained a significant concern for European producers. Higher electricity prices in May 2026 increased operating costs for facilities that rely on energy-intensive production and processing systems. Pharmaceutical manufacturing requires controlled operating conditions, specialized equipment, and quality assurance procedures, all of which contribute to overall production expenditure. Rising utility bills can therefore influence supplier pricing decisions even when demand growth is limited.

Consumer price inflation also remained relevant. Germany's CPI increased by 2.3% year-over-year in June 2026, highlighting continuing pressure on the broader cost of living. At the same time, consumer confidence declined to -14.6% in June 2026, reflecting cautious sentiment among households. Although pharmaceutical procurement is influenced by healthcare systems, institutional purchasing, and medical requirements rather than consumer confidence alone, weak sentiment can contribute to more conservative spending and inventory decisions across the wider economy.

The labor market offered some stability. Germany's unemployment rate remained at 3.8% in May 2026, while retail sales increased by 1.8% during the same month. These indicators suggested that some areas of economic activity remained resilient. Nevertheless, they did not fully offset concerns about manufacturing costs, weaker industrial activity, and soft demand across parts of the European chemical sector.

Germany's industrial production remained unchanged at 0.0% in May 2026, while chemical-sector exports declined during the first half of 2026. These conditions indicated a challenging environment for industrial suppliers. Weaker export activity can reduce production efficiency where facilities operate below their preferred utilization levels, potentially increasing unit costs. However, the precise effect on Ivermectin manufacturing depends on individual producers' capacity utilization, sourcing arrangements, and product mix.

Inventory management became another important factor during Q2 2026. Some buyers increased precautionary stocks to protect against potential supply disruptions and further price increases. These inventory builds supported short-term sales activity and helped suppliers clear available material. However, many purchasers remained cautious about carrying excess inventory because of financing costs, uncertain demand, and the risk of purchasing at elevated prices.

Consequently, precautionary buying did not necessarily indicate a sustained recovery in final consumption. Buyers increasingly prioritized essential requirements and shorter procurement cycles, while distributors monitored inventory turnover and supplier lead times. This approach limited the potential for demand-driven price acceleration even as manufacturers faced rising input expenses.

The European Ivermectin Price Trend therefore reflected a cost-driven increase rather than a broad-based surge in consumption. Manufacturers continued to face pressure from energy and chemical input prices, while weak demand and conservative inventory strategies constrained pricing flexibility. Further developments were likely to depend on energy-market movements, industrial activity, export performance, and the purchasing behavior of pharmaceutical distributors.

Why Did Ivermectin Prices Change in June 2026 in Europe?

The upward movement in European Ivermectin Prices during June 2026 was primarily linked to higher production costs, especially industrial inputs and electricity, while subdued demand limited further gains.

Industrial producer-price inflation: Germany's producer prices rose by 2.2% in May 2026, contributing to higher manufacturing expenses.
Elevated electricity costs: Higher energy expenses placed additional pressure on pharmaceutical processing, utilities, and facility operations.
Weak consumer confidence: Confidence declined to -14.6% in June 2026, reinforcing cautious purchasing behavior across the wider economy.
Limited industrial momentum: Industrial production was unchanged in May 2026, while chemical exports declined during the first half of the year.
Inventory caution: Buyers built precautionary stocks selectively but continued to favor lean inventories and essential purchasing.

These conditions supported higher supplier costs without generating equivalent demand-driven momentum. As a result, European Ivermectin Prices remained sensitive to production efficiency, contract negotiations, and changes in pharmaceutical procurement activity.

Global Factors Influencing the Ivermectin Price Trend

Several cross-regional factors shaped Ivermectin Prices during Q2 2026. Although North America, APAC, and Europe experienced different demand and manufacturing conditions, their markets remained connected through chemical input costs, international trade, energy prices, and pharmaceutical supply-chain decisions.

Raw Material and Feedstock Costs

Chemical intermediates and process materials are essential components of pharmaceutical ingredient manufacturing. Increases in feedstock prices can raise production costs and influence supplier quotations. During Q2 2026, higher input costs were a common factor supporting the upward movement of Ivermectin Prices across the three regions.

Energy and Manufacturing Expenses

Electricity, natural gas, process heating, and equipment operation contribute to industrial production costs. The impact of energy-price movements varies by region and facility. While lower natural gas prices provided some relief in the United States, higher electricity expenses remained a concern in North America and Europe.

Demand and Inventory Management

Demand conditions influenced the ability of manufacturers to pass higher costs on to buyers. Relatively supportive pharmaceutical purchasing in North America contrasted with weaker consumer demand in China and cautious procurement in Europe. Inventory decisions further shaped short-term trading activity, as buyers balanced supply security against the risk of holding expensive stocks.

Trade and Supply-Chain Diversification

Trade measures, freight expenses, supplier qualification requirements, and delivery reliability influenced sourcing decisions. Importers increasingly evaluated alternative suppliers and procurement routes to manage disruption risks. However, changing suppliers may involve additional compliance checks, testing, and logistics costs.

Industrial Activity and Production Capacity

Manufacturing activity affected the availability of chemical inputs and the efficiency of industrial supply chains. China's expanding industrial production supported its role as a major chemical supplier, while weaker industrial momentum in Germany created challenges for parts of the European manufacturing sector. These differences contributed to regional variations in Ivermectin Prices.

Book A Demo for Ivermectin Prices: https://www.chemanalyst.com/ChemAnalyst/PricingForm?Product=Ivermectin

Ivermectin Price Forecast: Outlook Beyond Q2 2026

The outlook for Ivermectin Prices beyond June 2026 will depend on the balance between manufacturing costs, pharmaceutical demand, supplier availability, and inventory behavior. Based on the conditions observed during Q2 2026, the market may continue to face upward cost pressure, although the pace and extent of price movements will likely differ across regions.

In North America, continued producer-price inflation and electricity expenses could keep manufacturing costs elevated. However, changes in natural gas prices, improvements in production efficiency, and supplier diversification may help moderate cost increases. Demand for pharmaceutical products will remain an important factor in determining whether manufacturers can pass additional expenses on to customers.

In APAC, China's chemical manufacturing capacity and export networks may continue to support supply availability. Nevertheless, subdued domestic retail demand could constrain the strength of demand-driven price increases. The direction of Chinese Ivermectin Prices will depend on feedstock costs, pharmaceutical ingredient production, export orders, and competition among qualified suppliers.

In Europe, the market may remain exposed to elevated energy and industrial input costs. If demand remains weak, manufacturers could face difficulty passing on all additional expenses. Buyers may continue to prioritize shorter inventory cycles, competitive quotations, and dependable delivery schedules. A recovery in industrial activity or stronger pharmaceutical procurement could improve market conditions, while persistent cost inflation could maintain upward pressure on supplier prices.

These expectations represent a directional assessment based on Q2 2026 market conditions rather than a quantified price forecast. Future price movements will depend on developments in raw material markets, production costs, trade conditions, and demand across the pharmaceutical supply chain.

Conclusion: Ivermectin Prices in Q2 2026

Ivermectin Prices increased across North America, APAC, and Europe during Q2 2026, driven primarily by rising production costs, higher chemical input expenses, and regional supply-chain developments. The United States experienced support from pharmaceutical demand and relatively stable employment conditions, while China's average FOB Ivermectin price reached approximately USD 98,000/MT amid higher industrial input costs and subdued domestic demand. In Germany, elevated electricity expenses and rising producer prices supported the upward trend, although weak confidence and cautious purchasing limited demand-side momentum.

Looking ahead, raw material prices, energy costs, supplier availability, trade conditions, and inventory management will remain important factors shaping the Ivermectin Price Trend. Pharmaceutical manufacturers, distributors, and procurement teams should monitor these indicators to evaluate sourcing risks, negotiate competitive contracts, and maintain reliable supply.

About Us:

Welcome to ChemAnalyst, a next–generation platform for chemical and petrochemical intelligence where innovation meets practical insight. Recognized as “Product Innovator of the Year 2023” and ranked among the “Top 100 Digital Procurement Solutions Companies,” we lead the digital transformation of the global chemical sector. Our online platform helps companies handle price volatility with structured analysis, real-time pricing, and reliable news and deal updates from across the world. Tracking over 500 chemical prices in more than 40 countries becomes simple and efficient with us.

Contact Us:

Address:

420 Lexington Avenue, Suite 300 New York, NY 10170 United States

Phone: +1 332 258 6602

Email: [email protected]

Website: https://www.chemanalyst.com/

LinkedIn: https://www.linkedin.com/company/chemanalyst/

Facebook: https://www.facebook.com/ChemAnalysts/

Twitter: https://x.com/chemanalysts

YouTube: https://www.youtube.com/@chemanalyst

Instagram: https://www.instagram.com/chemanalyst_